<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01972711</url>
  </required_header>
  <id_info>
    <org_study_id>SEP361-104</org_study_id>
    <nct_id>NCT01972711</nct_id>
  </id_info>
  <brief_title>Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single-dose, Study of the Effects of SEP 363856 and Amisulpride on BOLD-fMRI Signal in Healthy Male and Female Volunteers With High or Low Schizotype Characteristics.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the effects of a single dose of SEP-363856 in healthy male&#xD;
      and female volunteers with high or low schizotype characteristics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized, double-blind, placebo-controlled functional magnetic resonance&#xD;
      imaging (fMRI) study of the effects of a single dose of SEP-363856 and amisulpride on blood&#xD;
      oxygen level dependent (BOLD) signal in healthy male and female volunteers with high or low&#xD;
      schizotype characteristics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BOLD fMRI activity in key regions of interest (ROIs) while performing the Monetary Incentive Delay (MID), N-back, and Signal detection (SD) tasks after a single-dose of study medication</measure>
    <time_frame>Up to 6 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Behavioural performance in the MID task, includes measurements of trial accuracy, trial duration, trial reaction time and amount of money won.</measure>
    <time_frame>Up to 6 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavioural performance in the N-back task, includes measurements of accuracy (% correct for each trial type), reaction time and target sensitivity (d').</measure>
    <time_frame>Up to 6 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavioural performance in the SD task, includes measurements of correct and incorrect responses.</measure>
    <time_frame>Up to 6 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>SEP-363856</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-dose SEP-363856 50 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amisulpride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single-dose Amisulpride 400 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEP-363856</intervention_name>
    <description>SEP-36385625 as a single oral dose of 50 mg</description>
    <arm_group_label>SEP-363856</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amisulpride</intervention_name>
    <description>Amisulpride as a single oral dose of 400 mg</description>
    <arm_group_label>Amisulpride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single oral dose placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged 18 to 45 years, inclusive, at Day 1.&#xD;
&#xD;
          -  Subject must be healthy as determined by the Investigator, based on a medical&#xD;
             evaluation including medical history, physical examination, laboratory tests and&#xD;
             cardiac monitoring within four weeks of randomisation. A subject with a clinical&#xD;
             abnormality or laboratory parameters outside the reference range for the population&#xD;
             being studied may be included only if the Investigator considers that the finding is&#xD;
             unlikely to introduce additional risk factors and will not interfere with the study&#xD;
             procedures.&#xD;
&#xD;
          -  Subject must be normotensive with sitting (5 minutes) blood pressure between the range&#xD;
             of 90 to 150 mm Hg systolic, inclusive, and 60 to 90 mm Hg diastolic, inclusive, at&#xD;
             Screening.&#xD;
&#xD;
          -  Subject must have sitting (5 minutes) heart rate ≥ 50 beats per minute at Screening.&#xD;
&#xD;
          -  Subject must agree to use one of the following birth control/contraception methods&#xD;
             from Screening until 90 days after receiving study drug.&#xD;
&#xD;
          -  Female subject of child bearing potential (≤ 65 years) should be surgically sterile or&#xD;
             abstinent or, if sexually active, must use an adequate method of contraception in&#xD;
             addition to their partner(s) using a barrier method.&#xD;
&#xD;
          -  Male subject with female partner(s) of childbearing potential must take appropriate&#xD;
             precautions to avoid fathering a child and use barrier contraception, in addition to&#xD;
             their female partner(s) using another method.&#xD;
&#xD;
          -  Male subject must not donate sperm.&#xD;
&#xD;
          -  Acceptable forms of contraception are as follows:&#xD;
&#xD;
          -  Barrier methods: condoms, diaphragms, cervical caps; with a spermicide foam, gel,&#xD;
             film, cream or pessary.&#xD;
&#xD;
          -  Non-hormone containing intrauterine methods: intrauterine devices or systems.&#xD;
&#xD;
          -  Other: prescription oral contraceptives, contraceptive injections, contraceptive&#xD;
             implant, contraceptive vaginal ring, hormonal intrauterine device, double-barrier&#xD;
             method, contraceptive patch, or male partner sterilisation.&#xD;
&#xD;
          -  Subject must have normal ECG results, including QTcF &lt; 450msec (for men) or &lt; 470 ms&#xD;
             (for women) (based on the Fridericia correction where QTcF = QT/RR0.33) at Screening.&#xD;
&#xD;
          -  Subject must be a completely fluent English speaker who, in the opinion of the&#xD;
             Investigator, is capable of completing the fMRI and behavioural tasks.&#xD;
&#xD;
          -  Subject must be right-handed.&#xD;
&#xD;
          -  Subject must have acceptable weight as defined by BMI (weight [kg]/height [m]²) range&#xD;
             of 18 to 35 kg/m², inclusive at Screening.&#xD;
&#xD;
          -  Subject must be a non-smoker or light smoker (≤ 10 cigarettes per day).&#xD;
&#xD;
          -  Subject must have signed the informed consent form prior to the first study-related&#xD;
             procedure indicating they understand the purpose of and procedures required for the&#xD;
             study and are willing to participate in the study.&#xD;
&#xD;
          -  Subject in the low schizotypy group must have an SPQ score &lt; 10 at Screening.&#xD;
&#xD;
          -  Subject in the high schizotypy group must have an SPQ score &gt;43 at Screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject with a history of alcohol or substance dependence within the last 12 months&#xD;
             from Screening.&#xD;
&#xD;
          -  Subject with a positive urine drug screen at Screening or Day 1. One re-test within 1&#xD;
             to 3 days is permitted if positive result is believed to be due to licenced&#xD;
             opiate-based medication or ingestion of poppy seeds. In this event, re-test result&#xD;
             will be used for assessing entry criterion and must be completed prior to&#xD;
             randomisation.&#xD;
&#xD;
          -  Subject with a positive alcohol breath test at Screening or Day 1.&#xD;
&#xD;
          -  Female subject with a positive pregnancy test at Screening or Day 1.&#xD;
&#xD;
          -  Female subject currently pregnant or trying to get pregnant or currently breast&#xD;
             feeding.&#xD;
&#xD;
          -  Subject who consumes large amounts of caffeinated drinks (more than 8 cups of standard&#xD;
             caffeinated drinks (tea, instant coffee) or 6 cups of stronger coffee or other drinks&#xD;
             containing methylxanthines such as coca cola or Red Bull per day).&#xD;
&#xD;
          -  Subject with a relevant history, or presence upon clinical examination, of cardiac,&#xD;
             ophthalmologic, pulmonary, endocrine (diabetes), blood disease, gastro-intestinal,&#xD;
             hepatic or renal disease or other condition which in the opinion of the Investigator&#xD;
             could interfere with the test procedures.&#xD;
&#xD;
          -  Subject with a history of cancer, except for basal cell or Stage 1 squamous cell&#xD;
             carcinoma of the skin which has been in remission for at least 5 years prior to Day 1.&#xD;
&#xD;
          -  Subject meets the diagnostic criteria for schizophrenia, or any other psychotic&#xD;
             disorder, as determined by the SCID-I at Screening&#xD;
&#xD;
          -  Subject with a history of, or presents (in the opinion of the Investigator) with,&#xD;
             significant neurological or psychiatric conditions (such as stroke, traumatic brain&#xD;
             injury, depression, seizures, space occupying lesions, multiple sclerosis, Parkinson's&#xD;
             disease, vascular dementia, transient ischemic attack, schizophrenia, blackouts&#xD;
             requiring hospitalisation).&#xD;
&#xD;
          -  Subject with a history of positive HIV test.&#xD;
&#xD;
          -  Subject with a history of, or current condition of, migraine headaches or has&#xD;
             undergone operations to the head.&#xD;
&#xD;
          -  Subject with a significant hearing impairment which, in the opinion of the&#xD;
             Investigator, may interfere with the performance of the behavioural tasks or fMRI&#xD;
             tasks.&#xD;
&#xD;
          -  Subject with a significant visual impairment including colour blindness, or history of&#xD;
             ocular treatment including corrective laser eye surgery, or ongoing condition, which&#xD;
             in the opinion of the Investigator may interfere with the performance of the&#xD;
             behavioural tasks or fMRI tasks.&#xD;
&#xD;
          -  Subject received prescribed medication within 28 days prior to Day 1 (apart from the&#xD;
             contraceptive pill). Subjects who have taken prescription medication may still be&#xD;
             entered into the study, if, in the opinion of the Investigator, the medication&#xD;
             received will not interfere with the study procedures or compromise safety (see&#xD;
             Section 10.2, Concomitant Medications).&#xD;
&#xD;
          -  Subject received non-prescription medication, including supplements such as vitamins&#xD;
             and herbal supplements within 48 hours prior to Day 1 (apart from paracetamol).&#xD;
             Subjects who have taken non-prescription medication may still be entered into the&#xD;
             study, if, in the opinion of the Investigator, the medication received will not&#xD;
             interfere with the study procedures or compromise safety (see Section 10.2,&#xD;
             Concomitant Medications).&#xD;
&#xD;
          -  Subject received an experimental drug and / or used an experimental medical device&#xD;
             within 30 days of randomisation or within a period less than 5 times the drug's&#xD;
             half-life, whichever is longer.&#xD;
&#xD;
          -  Subject with a known hypersensitivity to SEP-363856 or amisulpride or any of their&#xD;
             excipients.&#xD;
&#xD;
          -  Subject with a history of severe drug allergy or hypersensitivity.&#xD;
&#xD;
          -  Subject who is unable or unwilling to comply with study procedures, including study&#xD;
             prohibitions and restrictions (see Section 10.2, Concomitant Medications and Section&#xD;
             10.3, Restrictions).&#xD;
&#xD;
          -  Subject with previous experience with the ETB.&#xD;
&#xD;
          -  Subject with a diagnosis of dyslexia.&#xD;
&#xD;
          -  Subject with a history of claustrophobia or inability to tolerate scanner environment.&#xD;
&#xD;
          -  Subject who fulfills any of the MRI contraindications on the standard site radiography&#xD;
             screening questionnaire (e.g. history of surgery involving metal implants).&#xD;
&#xD;
          -  Subject with a clinically relevant structural brain abnormality as determined by prior&#xD;
             MRI scan.&#xD;
&#xD;
          -  Subject with planned medical treatment within the study period that might interfere&#xD;
             with the study procedures.&#xD;
&#xD;
          -  Subject who is unlikely to comply with the clinical study protocol or is unsuitable&#xD;
             for any other reason, in the opinion of the Investigator.&#xD;
&#xD;
          -  Subject is a staff member or the relative of a staff member, or is in a subordinate&#xD;
             relationship with the Investigator.&#xD;
&#xD;
          -  Subject answers &quot;yes&quot; to &quot;Suicidal Ideation&quot; Items 4 or 5 on the C-SSRS.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director, SEP-363856, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sunovion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Psychiatry, University of Oxford, Warneford Hospital</name>
      <address>
        <city>Headington</city>
        <state>Oxford</state>
        <zip>OX3 7JX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Manchester, Neuroscience and Psychiatry Unit</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>October 24, 2013</study_first_submitted>
  <study_first_submitted_qc>October 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2013</study_first_posted>
  <last_update_submitted>February 22, 2016</last_update_submitted>
  <last_update_submitted_qc>February 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amisulpride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

